The FDA cleared the first generic versions of atomoxetine for attention-deficit/hyperactivity disorder (ADHD) in both children and adults, the agency announced. Four companies got the okay to market the drug in multiple dosing strengths: Apotex, Teva Pharmaceuticals USA, Aurobindo Pharma, and Glenmark Pharma. The branded product, Strattera, is made by Eli Lilly and was originally approved in 2002.